Metformin weight loss has always been a slightly awkward fact.
The drug is a decades-old diabetes workhorse. It is inexpensive, widely prescribed, and often produces modest weight reduction in people taking it. In the Diabetes Prevention Program, participants assigned to metformin lost an average of approximately 2.7% of their body weight after one year, compared with 0.43% in the placebo group.
That is modest beside semaglutide or tirzepatide. The biology behind it, however, remains surprisingly complicated.
A new Stanford-led study published online in Cell on October 22, 2026, identifies another piece of the puzzle. In mice, the weight effect associated with metformin depends in part on a transporter in the intestinal lining that allows an appetite-suppressing molecule to leave cells and enter circulation.
The molecule is called Lac-Phe, short for N-lactoyl-phenylalanine. It combines lactate and the amino acid phenylalanine and acts as a circulating metabolic signal.
It is not a peptide medicine, but it belongs in the broader conversation about how tissues communicate changes in metabolism and appetite.
The new paper, led by first author Shuke Xiao and senior author Jonathan Long, identifies MCT6, also known as SLC16A5, as an important intestinal Lac-Phe exporter.
The decisive body-weight experiments were performed in mice. The team also tested transport in laboratory systems, including human-derived cells, but did not establish MCT6’s contribution to weight loss in living human participants.
From a Sprint to a Pill Bottle
Lac-Phe first drew attention in 2022, when Long’s group and collaborators reported in Nature that the molecule rises in the blood after intense exercise.
The researchers observed the response across species, including humans, mice and racehorses. In obese mice, experimentally increasing Lac-Phe reduced food intake, body weight and adiposity.
The obvious nickname, an “exercise molecule,” stuck. But the discovery did not mean that Lac-Phe had been established as the explanation for exercise-related weight loss in people.
The story became more interesting in March 2024, when two complementary studies appeared in Nature Metabolism.
One, led by Xiao and Stanford collaborators, showed that metformin strongly increases Lac-Phe production through changes in cellular energy metabolism. In mice, the drug increased circulating Lac-Phe, reduced food intake and produced weight loss.
In one nine-day experiment, obese mice receiving metformin ate less and lost approximately two grams of body weight. Genetic disruption of Lac-Phe production made the mice resistant to the drug’s effects on appetite and weight.
A second study, led by Barry Scott and collaborators, investigated human data and found that circulating Lac-Phe increased with metformin treatment. Its analyses included observational cohorts and samples collected before and after metformin administration.
Those human findings established that metformin can raise the metabolite in circulation. They did not establish that Lac-Phe is responsible for a particular amount of weight loss in patients.
That left a mechanical question.
Lac-Phe is produced inside cells, including intestinal epithelial cells. For it to influence distant tissues, it must reach the circulation.
A molecule made inside a cell can only act as a circulating signal if it has a way to leave.
What the Cell Study Actually Showed About Metformin Weight Loss
The Stanford team’s answer is MCT6, a member of the monocarboxylate transporter family whose physiological function had remained poorly understood.
The October 2026 paper identifies MCT6 as a transporter capable of moving Lac-Phe across cell membranes and contributing to the metabolite’s release into circulation.
The researchers tested the transport mechanism using biochemical assays and cultured cells. Increasing MCT6 activity promoted Lac-Phe export, while disrupting the transporter reduced the movement of Lac-Phe out of cells.
They also identified additional N-lactoyl amino acids that MCT6 can transport, including Lac-Tyr and Lac-Trp. Unlike Lac-Phe, these compounds did not produce the same food-intake or body-weight effects in the reported experiments.
The mouse experiments supplied the more consequential result.
Mice fed a high-fat diet and lacking MCT6 throughout their bodies showed resistance to metformin-associated weight loss.
The researchers then removed MCT6 specifically from intestinal epithelial cells. Those mice also showed reduced metformin-induced circulating Lac-Phe and resistance to the drug-associated weight effect.
That intestine-specific result matters because it identifies the gut lining as an important location for the transport mechanism, rather than requiring a defect throughout the entire body.
The team then performed a particularly revealing rescue experiment.
When researchers administered Lac-Phe directly to MCT6-knockout mice receiving metformin, bypassing the impaired export step, the animals’ body-weight phenotype returned toward that seen in metformin-treated mice with intact MCT6.
The experimental logic is unusually clear: remove the transporter, observe resistance to the drug-associated weight effect, then bypass the transport step and restore the phenotype.
That is stronger evidence than simply finding two molecules that rise or fall together. It establishes an important causal role for MCT6-mediated Lac-Phe transport in the mouse model.
It does not establish that MCT6 is the only route for Lac-Phe export, or that this pathway explains all of metformin’s actions.
What it shows is that releasing a metabolite from a cell can be an independently regulated step between local metabolism and whole-body physiology.
Why a Diabetes Pill Is Part of the Obesity Science Story
The GLP-1 era has trained the public to think about weight loss in terms of powerful injectable medicines. Metformin is a reminder that older drugs can influence appetite through pathways they were never specifically designed to target.
GLP-1 itself is a gut hormone, and much of the current obesity pipeline attempts to amplify or combine signals involved in appetite and metabolic regulation.
Lac-Phe adds another kind of signal to that map: a small circulating metabolite rather than a conventional peptide hormone.
The distinction is important because it widens the question researchers can ask. Instead of only investigating which receptors control appetite, scientists can also examine how metabolism produces signaling molecules and how those molecules reach circulation.
Metformin’s relationship with Lac-Phe is particularly interesting because intense exercise also elevates the metabolite.
The October paper found that MCT6 contributes to maintaining circulating Lac-Phe levels following high-intensity exercise in mice, further connecting the transporter with metabolic responses beyond drug treatment.
But Lac-Phe is not the only candidate mechanism behind metformin-associated changes in appetite.
Earlier studies identified growth differentiation factor 15, or GDF15, as another important signal. Metformin increases circulating GDF15, and experiments disrupting GDF15 signaling have demonstrated effects on food intake and body weight in mice.
Other proposed contributors include intestinal metabolism and changes in the gut microbiome. These mechanisms may interact rather than represent competing explanations with only one possible winner.
The MCT6 finding therefore should not be interpreted as solving every part of metformin’s weight-loss biology.
What it does offer is a testable mechanism that may eventually help explain variation in drug response.
For example, researchers could investigate whether differences in human SLC16A5 function correlate with changes in circulating Lac-Phe or body weight during metformin treatment.
That remains a hypothesis. The October study did not demonstrate such a relationship in people.
The work also fits a broader research effort to understand appetite regulation and lasting weight control, a topic explored in our coverage of the ALV-100 PRESERVE obesity-maintenance trial.
The Limits Are the Size of a Mouse
It is worth being precise about scale.
The earlier metformin work measured weight changes in mice in grams over days. The new MCT6 study used cellular experiments and genetically modified mice to establish how a circulating metabolite gets out of intestinal cells.
Neither result provides evidence that manipulating MCT6 will produce clinically meaningful weight loss in humans.
Metformin-associated weight loss in people is real but generally modest compared with the reductions observed in modern incretin-drug trials.
A transporter that contributes to that modest response in rodents is a biological insight, not a new obesity treatment.
Several major questions remain unanswered.
The researchers did not demonstrate that people with reduced MCT6 activity lose less weight when taking metformin.
They did not establish what proportion of metformin-associated human weight loss is mediated by Lac-Phe rather than GDF15 or other pathways.
They also did not establish that raising MCT6 activity would increase circulating Lac-Phe safely or produce a useful treatment effect.
Nor did the study show that administering Lac-Phe as a supplement or therapeutic product is safe or effective for weight loss in people.
The human evidence supports metformin’s ability to raise circulating Lac-Phe. The causal weight-loss role of MCT6 remains a finding from experimental models.
The discovery explains how one appetite-related signal can leave the gut in mice. It does not prove that the same pathway controls weight loss in people.
What to Watch Next
The natural next steps are human ones.
Researchers could investigate whether genetic variants in SLC16A5 are associated with circulating Lac-Phe concentrations, appetite changes or weight response in people taking metformin.
Metabolic studies could also examine how MCT6 activity relates to intestinal Lac-Phe production under different nutritional conditions.
Exercise physiologists may want to investigate whether the transporter helps determine how much Lac-Phe appears in circulation after intense exercise in humans, and whether those concentrations correlate with subsequent food intake.
Those questions are plausible extensions of the study, not announced clinical programs or demonstrated therapeutic opportunities.
For now, the value of the discovery is conceptual.
It connects observations that had previously been studied separately: metformin changes intestinal metabolism, cells produce Lac-Phe, MCT6 helps export the molecule, and the resulting signal contributes to body-weight regulation in mice.
The broader lesson is that producing a metabolite is only part of the signaling problem. Cells must also release it in a form that allows other tissues to respond.
That resembles other unresolved questions in exercise metabolism. For example, our earlier coverage of MOTS-c and exercise-associated fatty-liver changes examined another proposed molecular connection that still requires stronger human evidence.
These studies do not establish interchangeable treatments. They show how much of the metabolic conversation between tissues remains to be mapped.
For metformin, the October 2026 findings identify an important transport step in a pathway already linked to the drug’s effects on appetite and weight.
Stanford found the gut’s Lac-Phe exit door in mice.
Whether that same door helps explain why people lose weight on metformin is the question worth following.
Primary source: Xiao S et al. MCT6 is an intestinal Lac-Phe exporter required for metformin-associated weight loss. Cell. Published online October 22, 2026.
Foundational Lac-Phe discovery: Li VL et al. An exercise-inducible metabolite that suppresses feeding and obesity. Nature. June 15, 2022.
Metformin mouse-mechanism study: Xiao S et al. Lac-Phe mediates the effects of metformin on food intake and body weight. Nature Metabolism. March 18, 2024.
Human metabolite study: Scott B et al. Metformin and feeding increase levels of the appetite-suppressing metabolite Lac-Phe in humans. Nature Metabolism. March 18, 2024.
Stanford background reporting: Stanford Medicine — Weight Loss Caused by Common Diabetes Drug Tied to Anti-Hunger Molecule. March 18, 2024.
Additional mechanistic context: Coll AP et al. GDF15 mediates the effects of metformin on body weight and energy balance. Nature. Published online December 25, 2019.
